Current filters:

AmgenGilead Sciences

1 to 9 of 23 results

Pharmaceutical companies to benefit from new blood cancer drugs


Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

More cancer and HIV drugs added to Australian PBS


More than 160,000 patients will benefit directly from changes to Australia’s Pharmaceutical Benefits…

AmgenAnti-viralsAsia-PacificGilead SciencesOncologyPharmaceuticalPrezistaPricingRegulationXgeva

Biotech posts weak performance in April, reflecting toll of US health care reform


Despite the pop in the shares of Dendreon on the announcement that its prostate cancer therapy Provenge…

AmgenBiotechnologyDendreonFinancialGilead Sciences

Biotech down on weaker 1st-qtr drug sales, but broader market stays on a roll


April was Wall Street's best month in nine years, which analysts believe sends the strongest signal yet…

AmgenGenzymeGilead SciencesGiliad ScienceslenalidomideRevlimid

Biotech avoids fall out from tough quarter for capital markets, says Burrill report


The biotechnology industry came through a very turbulent 2008 first quarter relatively unscathed with…

AmgenGenentechGilead SciencesGiliad Sciences

Biotech has positive year, despite weak 2007 fourth quarter, says Burrill


"The biotech industry finished the year in good shape with the Burrill Biotech Select Index, a price-weighted…

AmgenAranespAstraZenecaDarbepoetin AlfaEpoetin AlfaEpogenGenentechGilead SciencesGiliad ScienceslenalidomideProcritRevlimidRoche

Stock Commentary - Europe - week to Oct 2, 2006


NEW YORK: equities started the reporting period to October 2 in bullish mood, helped by better-than-expected…

AmgenAvastinbevacizumabBiogen IdeccetuximabErbituxGenentechGilead SciencesGiliad SciencesMerck KGaANatalizumabPanitumumab Injection for Intravenous UseRofecoxibTysabriVectibixVioxx

1 to 9 of 23 results



Back to top